Abstract: Provided herein are topical formulations including a compound of formula (I) and methods of using these topical formulations for the treatment of skin diseases, wherein the topical formulations include non-aqueous gel, aqueous gel, and emulsion-based formulations; and the compound of formula (I) is represented by wherein R1, R2, R2a, R3, R3a, and R3b are as defined and described herein.

Abstract: The present invention relates to pharmaceutical compositions, such as topical pharmaceutical compositions, comprising certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.

Abstract: The present invention relates to pharmaceutical compositions, such as topical compositions, comprising certain imidazo [1,2-b] pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising compounds of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: Embodiments of topical formulations for administering cerdulatinib or a pharmaceutically acceptable salt, hydrate or solvate thereof are disclosed. Embodiments of methods for preparing the topical formulations are also disclosed. The disclosed formulations are suitable for the treatment of dermatologic conditions such as atopic dermatitis.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: The present invention provides topical, e.g., dermal, pharmaceutical compositions comprising an active agent. The present invention further provides methods of preparing such compositions and methods of treating a disease, disorder, or condition, such as a skin disease, using the same.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.